

**For Immediate Release**

January 2, 2009

**Contact:**

Mary Kuramoto  
513-579-9911 x 2523  
m.kuramoto@medpace.com

**Medpace recognized with two awards for achieving outstanding revenue growth in the Cincinnati business community**

**Cincinnati, OH ( January 2, 2009)** - Medpace, Inc., a leading full-service global clinical research organization, today announced they were recognized by the Fast 55 as the fastest growing privately held company in 2008, a business award sponsored by the Cincinnati Business Courier. In a separate award Medpace was named a member of the Deloitte Cincinnati USA 100, coming in at number 79 for outstanding revenue growth as a member of the top 100 privately held companies in the Cincinnati area. This is the second year for Medpace recognition in the Fast 55 and their first year in the Deloitte 100.

Dr. August Troendle, President and CEO, anticipates strong revenue growth to continue into 2009 and beyond. "We've been growing at about 35% a year, I would expect that it would come down somewhat but we should be able to continue at a rate of 25% per year for the next few years."

"We've really focused on growing our expertise and bringing folks into our company who have good therapeutic expertise," said Kay Nolen, Medpace general counsel. "We've developed some pretty long-term relationships with the sponsoring pharmaceutical and biotech companies with whom we work."

Jeff Martini, CFO commented, "We see the industry growing 15-20 percent a year over the next two to five years, and we expect to achieve a consistent revenue growth in excess of industry averages."

Medpace was honored locally during November and December respectively at the annual Deloitte Cincinnati USA 100 and the Cincinnati Business Courier Fast 55 event.

**ABOUT MEDPACE**

Medpace is a leading global full-service clinical research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, oncology and nephrology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

Medpace provides centralized image management and reading from Imagepace, centralized laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology.

**Visit the Medpace website at [www.medpace.com](http://www.medpace.com)**